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Summary and Implications
The data demonstrate that mild fatty liver is associated
with decreased general health and reproductive performance
as evidenced by more days to first estrus and service, more
days open, decreased conception, increased number of days
with elevated body temperature at days 9 - 22 postpartum,
and increased incidence of mastitis at days 32 – 150
postpartum. The latter two were decreased in dairy cows
with mild fatty liver injected with 15 mg/d of glucagon
during weeks 2 and 3 postpartum. Therefore, treatment of
mild fatty liver with exogenous glucagon or better
prevention of fatty liver might improve health and
reproductive performance of lactating dairy cows, thereby
preventing loss of income of dairy farmers.
Introduction
Fatty liver is a metabolic disease that affects up to 50%
of dairy cows in early lactation. Fatty liver is associated
with an increased incidence and duration and decreased
treatment success of infectious and metabolic diseases, such
as mastitis, metritis, and ketosis, as well as decreased
reproductive performance in affected cows. A major reason
for this association is that hepatic lipid accumulation can
impair liver function, such as synthesis and
biotransformation of metabolites and proteins and the
detoxification and excretion of toxic waste products and
xenobiotics, which, in turn, can compromise immune
competence and ovarian function.
A previous study from our group demonstrated that
severe fatty liver and ketosis can be treated by continuous,
intravenous infusions of 10 mg/d of glucagon for 14 days.
In that study, cows were induced artificially into fatty liver
and ketosis, however, by feed restriction and administration
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of 1,3-butanediol, and the effects on health and reproduction
were not determined. The objectives of the current study
was to determine whether a) mild fatty liver is associated
with decreased health status (mastitis, elevated body
temperature, and ketosis) and reproductive performance
(days to first observed estrus, first service, days open,
number of services, conception rate after first service, and
overall conception rate) and b) whether glucagon injected
subcutaneously at 7.5 or 15 mg/d for 14 days starting at day
8 postpartum could decrease some of the detrimental
associations of mild fatty liver on health and reproductive
performance.
Materials and Methods
For the experiment, 32 Holstein dairy cows were used
that were 32 – 74 months of age, weighed 1190 – 1725 kg,
had a body condition score of 3.00 – 4.25 on a 1 -5 scale,
and had completed 1-4 lactations. For the last 4 weeks
prepartum, each cow was offered individually, in addition to
hay and the total mixed ration that was formulated to meet
NRC requirements, 6 kg of cracked corn daily to potentially
increase the incidence of mild fatty liver. All cows were
visually healthy before parturition. At day 8 postpartum,
cows were divided into two groups depending on their liver
triacylglycerol concentrations (cutoff value of 1% liver wet
weight) at day 8 postpartum. Cows with normal liver (n = 8;
Saline Normal) and triacylglycerol concentrations <1% of
liver wet weight were injected subcutaneously with 60 ml of
0.15 M NaCl every 8 hours (6:00, 14:00, and 22:00 for 14
days starting at 14:00 of day 8 postpartum. Cows with mild
fatty liver (n = 24; 8 cows randomly assigned to each
treatment group) and triacylglycerol concentrations of 1 -
10% of liver wet weight were injected with 0 (Saline
Susceptible), 2.5 (7.5 mg/d), or 5 (15 mg/d) mg of
lyophilized glucagon. All cows were managed and treated in
accordance with guidelines established by the Iowa State
University Committee on Animal Care.
Cows were monitored twice daily for flakes in the milk
and once daily at 9:00 for body temperature and urinary
acetoacetate concentrations. As an indicator of ketosis,
Ketostix® strips (Bayer Corporation, Tarrytown, NY) were
used. Mastitis was defined by flakes in the milk or a somatic
cell count in milk of >1,000,000 per ml. Milk samples were
analyzed for somatic cell count at two consecutive milking
at days 3, 8 (before first injection of glucagon), 11, 15, 22
(before last injection), 25, 28, 36, and 43 postpartum by
mid-infrared spectrophotometry (Milk-O-Scan 203; Foss
Food Technology, Eden Prairie, MN).
Estrus behavior was monitored for 1 hour twice daily.
The reproductive tract was examined by rectal palpation and
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ultrasound by a veterinarian every 2 weeks beginning at 20
days postpartum. Cows that were at least 42 days
postpartum, were confirmed open, and had at least one
corpus luteum were injected subcutaneously with 5 ml of
Lutalyse® (50 mg/ml PGF2_; Pharmacia & Upjohn,
Kalamazoo, MI) every 14 days until they showed signs of
estrus and then were inseminated. Cows that were at least 45
days postpartum were inseminated 12 hours after they
allowed mounting. Cows whose previous insemination
passed at least 35 days without further estrus were examined
for pregnancy by palpation and ultrasound.
Chi-square tests were used to compare treatment group
means of incidence rates for health status (mastitis, body
temperatures >39.5 °C, and urinary concentrations >40
mg/dl) and reproductive performance parameter (conception
rate after the first service, and overall conception rate). A t-
test was used to compare average lengths of time with body
temperatures >39.5 °C of treatment groups. Days to first
heat, days to first service, and days open were assumed
Weibull distributed, and treatment means were compared by
using a chi-square test.
Results and Discussion
The data demonstrate that non-treated mild fatty liver
was associated with increased incidence of mastitis from
days 23 – 150 postpartum (Table 1). Treatment of mild fatty
liver with subcutaneous injections of glucagon, in particular
at 15 mg/d, decreased the incidence of mastitis (Table 1).
The association of mild fatty liver with increased incidence
of mastitis from days 23 – 150 postpartum seems surprising
because, at days 23 – 42 postpartum, cows had normal liver
triacylglycerol concentrations. A possible reason for the
higher incidence of mastitis in cows with non-treated mild
fatty liver is that mild fatty liver might compromise the
immune response to mammary infections, which originated
from the peripartal period (Table 1). This possibility is
supported by the decreased number of days with elevated
body temperatures at 9 – 22 days postpartum of cows with
normal liver and cows with mild fatty liver receiving 15
mg/d of glucagon.
Cows with mild fatty liver had a decreased reproductive
performance (Table 2). The decreased reproductive
performance was associated with a higher incidence of
mastitis and a longer period of time in negative energy
balance. Five of the 6 cows that did not conceive had
mastitis at days 43 – 150 postpartum, whereas only 8 of the
24 cows that conceived had mastitis (P ≤ 0.03). Fifteen of
the 22 cows with mild fatty liver that were inseminated had
a lower body weight at days 23 – 42 postpartum than at days
9 – 22, whereas the same was true for only 2 of 8 cows with
normal liver (P ≤ 0.03). Mastitis and negative energy
balance both are associated with decreased signs of estrus,
conception rate, and embryo survival rates. Subcutaneous
injections of glucagon did not improve reproductive
performance of cows with mild fatty liver (Table 2). We
attribute the lack of positive effects of exogenous glucagon
on reproductive parameters to the fact that glucagon did not
decrease the length of time during which cows were in
negative energy balance. In another study from our group,
injections of 15 mg/d of glucagon for 14 days beginning at
day 2 postpartum prevented mild fatty liver. Therefore,
exogenous glucagon, given directly after calving for 14
days, might improve reproductive performance. Overall, the
results indicate that subcutaneous injections of 15 mg/d of
glucagon could alleviate some of the detrimental impacts of
mild fatty liver on health and reproduction and, therefore,
could improve overall performance and profitability of
lactating dairy cows.
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Table 1. Health status of cows with normal liver (Saline Normal) or mild fatty liver (Saline Susceptible, 7.5 mg/d
Glucagon, 15 mg/d Glucagon) receiving either saline or glucagon at 7.5 or 15 mg/d or saline for 14 days beginning at
day 8 postpartum
Treatment Type III SS P > Fa
Saline
Normal
Saline
Susceptible
7.5 mg/d
Glucagon
15 mg/d
Glucagon
C1 C2 C3
(n = 8) (n = 8) (n = 8) (n = 8)
Incidences: Number of cows
  Before injection period (days 0-8 postpartum):
    Mastitis 4 5 4 6 NS NS NS
    Body temp.>39.5°C 5 6 6 5 NS NS NS
    Acetoac. >40 mg/dla 0 0 2 4 NS NS 0.02
  During injection period (days 9-22 postpartum):
    Mastitis 0 2 1 0 NS NS NS
    Body temp.>39.5°C 8 6 6 6 NS NS NS
    Acetoac. >40 mg/dla 1 1 3 3 NS NS NS
  After injection period (days 23-42 postpartum):
    Mastitis 0 4 1 0 0.02 NS 0.02
    Body temp.>39.5°C 2 2 4 3 NS NS NS
    Acetoac. >40 mg/dl 1 0 1 1 NS NS NS
  During insemination and conception period (days 43-150 postpartum):
    Mastitis 3 7 2 3 0.04 0.01 0.04
Time length: Days per week (mean ± SEM)
  During injection period (days 9-22 postpartum):
    Body temp.>39.5°C 2.0 ± 0.5 3.9 ± 0.6 3.0 ± 0.6 1.9 ± 0.5 0.02 NS 0.02
  After injection period (days 23-42 postpartum):
    Body temp.>39.5°C 0.4 ± 0.7 0.5 ± 0.6 1.2 ± 0 .5 0.9 ± 0.5 NS NS NS
aC1: contrast between Saline Normal and Saline Susceptible (association with Susceptibility); C2: contrast between 7.5 mg/d
Glucagon and Saline Susceptible (effect of 7.5 mg/d glucagon); C3: contrast between 15 mg/d Glucagon and Saline
Susceptible (effect of 15 mg/d glucagon); NS = not significant at P > 0.05; burinary acetoacetate concentrations >40 mg/dl.
Table 2. Reproductive health and performance of cows with normal liver (Saline Normal) or mild fatty liver (Saline
Susceptible, 7.5 mg/d Glucagon, 15 mg/d Glucagon) receiving either saline or glucagon at 7.5 or 15 mg/d or saline for
14 days beginning at day 8 postpartum
Treatments Type III SS P > Fa
Saline
Normal
Saline
Susceptible
7.5 mg/d
Glucagon
15 mg/d
Glucagon
C1 C2 C3
(n = 8) (n = 8) (n = 7) (n = 7)
Days postpartum (mean ± SEM)
Reproduction:
  First estrus 44 ± 5 54 ± 8 56 ± 6 51 ± 4 0.04 NS NS
  First service 53 ± 2 81 ± 12 74 ± 11 73 ± 10 0.003 NS NS
  Days open 82 ± 24 105 ± 24 137 ± 17 104 ± 26 0.01 NS NS
  Services (n/cow) 1.5 ± 0.4 2.6 ± 0.6 3.3 ± 0.7 2.7 ± 0.8 NS NS NS
  Conception rate: Number of cows
    First service 5 4 3 3 NS NS NS
    Overall 8 5 6 5 0.05 NS NS
a C1: contrast between Saline Normal and Saline Susceptible (association with Susceptibility); C2: contrast between 7.5 mg/d
Glucagon and Saline Susceptible (effect of 7.5 mg/d glucagon); C3: contrast between 15 mg/d Glucagon and Saline
Susceptible (effect of 15 mg/d glucagon); NS = not significant at P > 0.05.
